Login to Your Account



Pharma: Other News To Note


Monday, July 1, 2013
Glaxosmithkline plc, of London, was granted breakthrough-therapy designation by the FDA for drisapersen for the potential treatment of patients with Duchenne's muscular dystrophy. Phase II U.S. and rest-of-world Phase III data on drisapersen are expected to report in the third and fourth quarters, respectively, of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription